Format

Send to

Choose Destination
J Surg Oncol. 2013 Nov;108(6):398-402. doi: 10.1002/jso.23409. Epub 2013 Aug 23.

Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study.

Author information

1
Department of Medical Oncology and Haematology, Charité-Universitätsmedizin Berlin, Germany.

Abstract

BACKGROUND:

Long-term survival (LTS) in patients (pts) with pancreatic cancer is still uncommon, little data is available to identify long-term survivors. The CONKO-001 study, which established gemcitabine after resection as adjuvant therapy, may provide data to answer this question.

METHODS:

CONKO-001 pts with an overall survival ≥5 years were compared to those who survived <5 years. Central re-evaluation of primary histology was performed. Univariate analysis with the χ(2) -test identified qualifying factors. Logistic regression was used to investigate the influence of these covariates on LTS.

RESULTS:

Of the evaluable 354 CONKO-001 pts, 54 (15%) with an overall survival ≥5 years were identified. It was possible to obtain tumor specimens of 39 pts (72%). Histological re-evaluation confirmed adenocarcinoma in 38 pts, 1 showed a high-grade neuroendocrine tumor. Univariate analysis for all 53 LTS pts with adenocarcinoma compared to the remaining 300 non-LTS pts revealed as relevant active treatment, tumor grading, tumor size, lymph nodes. No significance could be demonstrated for resection margin, sex, age, Karnofsky performance status, CA 19-9 at study entry. In multivariate analysis, tumor grading, active treatment, tumor size, lymph node involvement were independent prognostic factors for LTS.

CONCLUSION:

Long-term survival can be achieved in adenocarcinoma of the pancreas.

KEYWORDS:

adjuvant therapy; gemcitabine; rate of cure

PMID:
24038103
DOI:
10.1002/jso.23409
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center